Cardiovascular disease & MACE prevention
Where peptides — especially semaglutide — now sit inside the standard-of-care stack for preventing major adverse cardiovascular events.
What changes during this transition
Cardiovascular disease is the leading cause of death worldwide, and the standard-of-care stack for preventing major adverse cardiovascular events (MACE — CV death, non-fatal MI, non-fatal stroke) is one of the most studied and best-evidenced areas of modern medicine. For primary prevention with elevated risk: statins (FDA-approved since 1987, Tier 1 for LDL-C reduction and MACE prevention), blood pressure control via ACE-inhibitors / ARBs / other antihypertensives, glycemic control if diabetic, smoking cessation, lifestyle medicine. For secondary prevention after established CVD: high-intensity statin, dual antiplatelet therapy post-stent or per ACS protocol, ACEi or ARB, beta-blockade where indicated, cardiac rehab, and increasingly SGLT2 inhibitors (empagliflozin / dapagliflozin) for heart failure and CKD secondary prevention. PCSK9 inhibitors (Repatha, Praluent), inclisiran, ezetimibe, and icosapent ethyl (Vascepa, off REDUCE-IT) layer on top for residual-risk and genetic-dyslipidemia contexts. None of that has been displaced by anything in the peptide library. What has changed is that one peptide — semaglutide — now sits inside the secondary-prevention conversation as a Tier 1 approved intervention. SELECT (Lincoff 2023 NEJM, n=17,604) showed 20% relative MACE reduction in adults with overweight/obesity + established CVD without diabetes, and the FDA expanded the indication in 2024. AHA's 2024 statement and the ADA 2026 / ESC updates integrate GLP-1 receptor agonists as cardiovascular-prevention therapy. This is the first weight-loss drug to demonstrate hard CV-outcome benefit, and it represents a real paradigm shift — but it represents an addition to the secondary-prevention stack, not a substitution. Statin intensity, antiplatelet adherence, BP control, and cardiac rehab all stay exactly where they are. Tirzepatide sits one rung down at Tier 2: strong mechanism case, deeper weight loss than semaglutide, favorable cardiometabolic profile, but the dedicated CV-outcome trials (SURPASS-CVOT, SURMOUNT-MMO) haven't read out yet. Cardiology consensus today defaults to semaglutide for the secondary-prevention indication because that's where the FDA-approved evidence sits. Tesamorelin lives at Tier 3 — approved for HIV-associated lipodystrophy with VAT-reduction efficacy, with a plausible surrogate-improvement chain to CV-risk but no MACE-outcome trial and a glucose-handling caveat that interacts with the diabetic-CVD overlap. B12-methylcobalamin lives at Tier 2 for confirmed-deficiency repletion (MMA + homocysteine), with mixed RCT support for the homocysteine-lowering strategy in non-deficient CVD prevention. What's NOT surfaced here: BPC-157. Community framing claims endothelial-healing and atherosclerosis-prevention benefits drawn from rodent vascular work, but no human CV-outcome data exists, and two mechanism-direction concerns (coronary-steal physiology in flow-limiting stenosis, VEGF-driven intraplaque neovascularization as a plaque-destabilization mechanism) make surfacing it as a discovery card editorially misleading. The substrate exists for honest /ask answers when users probe; the browse page does not promote it.
Important caveat
Standard-of-care comes first, every time. Statins, antiplatelet therapy, ACE-inhibitors / ARBs, beta-blockade, SGLT2 inhibitors for HF/CKD, BP control, glycemic control if diabetic, smoking cessation, cardiac rehab — these are the load-bearing interventions, and no peptide on this page displaces any of them. SELECT excluded NYHA IV heart failure, severe renal impairment, and active eating disorders — if you live in those exclusions, you're outside the trial population and semaglutide-for-MACE is extrapolation, not approved-evidence. Primary prevention (no known CVD), secondary prevention (post-MI, post-stroke, post-stent, established CAD/PAD), heart failure with reduced or preserved ejection fraction, and atrial fibrillation are clinically distinct workups with distinct standard-of-care stacks — a peptide conversation in any of them happens after cardiology has the primary plan in place, not before. Familial hypercholesterolemia and Lp(a) elevation are genetic-dyslipidemia contexts where PCSK9 inhibitors and emerging Lp(a)-lowering therapeutics (olpasiran, lepodisiran) are the relevant lever, not anything on this page. Smoking cessation outranks every peptide on this page by a wide margin.
Peptides editorially relevant to cardiovascular disease & mace prevention
4 peptides from the library — each evidence-tiered honestly.
- SemaglutideTier 1
GLP-1 receptor agonist
The most-studied GLP-1 agonist in modern medicine, with Tier 1 evidence for diabetes, weight loss, and major adverse cardiovascular events.
- TirzepatideTier 1
GLP-1 / GIP dual agonist
FDA-approved dual incretin agonist with the strongest weight-loss and glycemic data in this library.
- TesamorelinTier 1
GHRH analog
FDA-approved for HIV-associated lipodystrophy. Off-label use for general fat loss is meaningfully less supported.
- B12 (Methylcobalamin)Tier 1
Vitamin (methylcobalamin)
Vitamin B12 in the methyl form. Solid evidence for treating documented deficiency and pernicious anemia. The wellness-clinic 'energy injection' market for non-deficient adults has no clinical-trial support.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.